破坏NKG2A:HLA-E相互作用以增强抗癌免疫力的策略。 - Suppr

Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.

作者信息

Fisher Jack G, Graham Lara V, Blunt Matthew D

出版信息

Oncotarget. 2024 Jul 17;15:501-503. doi: 10.18632/oncotarget.28610.

DOI:10.18632/oncotarget.28610

PMID:39018202

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11254306/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb15/11254306/430bca50d44b/oncotarget-15-28610-g001.jpg

相似文献

Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.

Oncotarget. 2024 Jul 17;15:501-503. doi: 10.18632/oncotarget.28610.

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody.

Mol Ther. 2024 Aug 7;32(8):2711-2727. doi: 10.1016/j.ymthe.2024.06.034. Epub 2024 Jun 27.

Monalizumab: inhibiting the novel immune checkpoint NKG2A.

J Immunother Cancer. 2019 Oct 17;7(1):263. doi: 10.1186/s40425-019-0761-3.

Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.

Neoplasia. 2011 Sep;13(9):822-30. doi: 10.1593/neo.101684.

Structure of the murine CD94-NKG2A receptor in complex with Qa-1 presenting an MHC-I leader peptide.

FEBS J. 2024 Apr;291(7):1530-1544. doi: 10.1111/febs.17050. Epub 2024 Jan 10.

NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.

Transl Res. 2022 Feb;240:64-86. doi: 10.1016/j.trsl.2021.10.006. Epub 2021 Oct 29.

Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function.

Blood Adv. 2024 Oct 22;8(20):5382-5399. doi: 10.1182/bloodadvances.2024013508.

SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression.

Emerg Microbes Infect. 2024 Dec;13(1):2361019. doi: 10.1080/22221751.2024.2361019. Epub 2024 Jun 27.

Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.

J Clin Invest. 2019 Mar 12;129(5):2094-2106. doi: 10.1172/JCI123955. Print 2019 May 1.

A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application.

Front Immunol. 2024 Aug 20;15:1331518. doi: 10.3389/fimmu.2024.1331518. eCollection 2024.

引用本文的文献

Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.

Nat Rev Immunol. 2025 Sep 3. doi: 10.1038/s41577-025-01218-6.

本文引用的文献

CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma.

Leukemia. 2024 Aug;38(8):1777-1786. doi: 10.1038/s41375-024-02303-w. Epub 2024 Jun 20.

Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance.

Cell Discov. 2024 Feb 9;10(1):16. doi: 10.1038/s41421-024-00646-3.

NKG2ACD8 T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma.

J Immunother Cancer. 2024 Jan 23;12(1):e008368. doi: 10.1136/jitc-2023-008368.

Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.

Immunity. 2023 Dec 12;56(12):2816-2835.e13. doi: 10.1016/j.immuni.2023.11.008.

The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent.

Cell Rep. 2023 Dec 26;42(12):113516. doi: 10.1016/j.celrep.2023.113516. Epub 2023 Dec 3.

Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies.

EMBO Mol Med. 2023 Nov 8;15(11):e17804. doi: 10.15252/emmm.202317804. Epub 2023 Oct 2.

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.

Leukemia. 2023 Oct;37(10):2036-2049. doi: 10.1038/s41375-023-01984-z. Epub 2023 Aug 1.

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells.

Sci Rep. 2023 Jun 29;13(1):10555. doi: 10.1038/s41598-023-37779-6.

Intracellular trafficking of HLA-E and its regulation.

J Exp Med. 2023 Aug 7;220(8). doi: 10.1084/jem.20221941. Epub 2023 May 4.

Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance.

Cancer Cell. 2023 Feb 13;41(2):272-287.e9. doi: 10.1016/j.ccell.2023.01.001. Epub 2023 Jan 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献